Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Entera Bio ( (ENTX) ) has issued an update.
Entera Bio reported first-quarter 2026 results on May 8, 2026, highlighting progress across its oral peptide pipeline, led by EB613, an oral anabolic tablet for postmenopausal osteoporosis. In March 2026 the company submitted a streamlined Phase 3 protocol and extension study design for EB613 to the FDA and completed a Phase 1 bridging study supporting advancement of a single-tablet formulation into Phase 3, while also presenting new EB612 and EB618 data to major endocrine meetings.
The company deepened its 50/50 partnership with OPKO on EB612, targeting an IND filing in late 2026, advanced preclinical work on EB618 for obesity and metabolic disease, and strengthened governance with the appointments of industry veterans Geno J. Germano as chairman and Steve Rubin to the board in February 2026. Entera closed the quarter with $11.9 million in cash, rising to $20.4 million by May 8, 2026 after a BVF-led private placement, and said its funds should support operations through the first quarter of 2027 despite higher R&D spend and a wider quarterly net loss of $3.5 million.
The most recent analyst rating on (ENTX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Entera Bio stock, see the ENTX Stock Forecast page.
Spark’s Take on ENTX Stock
According to Spark, TipRanks’ AI Analyst, ENTX is a Neutral.
The score is held down primarily by weak financial performance (persistent losses and cash burn, sharply lower revenue) and an overall bearish longer-term technical trend (below key moving averages with negative MACD). Positive corporate developments (financing to support Phase 3 and favorable pipeline/regulatory progress) provide some offset, while valuation metrics provide limited support due to negative earnings and no dividend data.
To see Spark’s full report on ENTX stock, click here.
More about Entera Bio
Entera Bio Ltd. is a clinical-stage biotechnology company specializing in oral peptide and protein replacement therapies targeting significant unmet medical needs where tablet formulations could replace injections. Leveraging its proprietary N-Tab platform, the company is advancing a pipeline led by EB613 for osteoporosis, EB612 for hypoparathyroidism, and additional oral peptides for obesity, metabolic syndromes and rare malabsorption conditions in collaboration with OPKO Health Inc.
Average Trading Volume: 187,458
Technical Sentiment Signal: Sell
Current Market Cap: $63.87M
For detailed information about ENTX stock, go to TipRanks’ Stock Analysis page.